Next Article in Journal
The Protective Role of Bacillus velezensis A2 on the Biochemical and Hepatic Toxicity of Zearalenone in Mice
Previous Article in Journal
Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors
Article Menu

Export Article

Open AccessArticle
Toxins 2018, 10(11), 448; https://doi.org/10.3390/toxins10110448

AbobotulinumtoxinA: A New Therapy for Hip Osteoarthritis. A Prospective Randomized Double-Blind Multicenter Study

1
Neurological Unit 1, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, 20133 Milan, Italy
2
Neurological Unit, “S.Maria della Misericordia” University Hospital, 33010 Udine, Italy
3
Physical Medicine and Rehabilitation Unit, “Riuniti” Hospital, 71122 Foggia, Italy
4
Neurological Unit, “Villa Rosa” Rehabilitation Hospital (APSS TN), 38057 Trento, Italy
5
Physical Medicine and Rehabilitation Unit, “Santa Corona” Hospital, (Local Health Agency 2 Savonese), 17027 Pietra Ligure (SV), Italy
6
Neurological Unit, “Dell’Angelo” Hospital, 30174 Venice, Italy
7
Institute of Orthopedic Surgery, “S.Maria della Misericordia” University Hospital of Udine, 33010 Udine, Italy
*
Author to whom correspondence should be addressed.
Received: 13 October 2018 / Revised: 25 October 2018 / Accepted: 26 October 2018 / Published: 31 October 2018
(This article belongs to the Special Issue Botulinum Toxin: The Role in Neuro-Rehabilitation)
Full-Text   |   PDF [661 KB, uploaded 13 November 2018]   |  

Abstract

Hip Osteoarthritis (OA) causes pain and disability. Here we evaluate abobotulinumtoxinA (Dysport®) (AboBoNT-A) injections versus placebo as a novel treatment option to improve hip range of motion, pain and quality of life. This prospective randomized double-blind multicenter study (EudraCT # 2012-004890-25) recruited 46 outpatients with hip OA who were randomized 2:1 to the Treatment Group (TG; 31 subjects), or the Placebo Group (PG; 15 subjects). The TG received 400 U of AboBoNT-A injected into the adductor muscles, and the PG received placebo solution. The primary endpoints were the difference in Harris Hip Score (HHS) and Visual Analogic Scale for pain (VAS) at Week 4 between groups (TG vs. PG). Secondary endpoints were the change from baseline in HHS, VAS pain, Medical Research Council scale for muscle strength (MRC) and Short Form scale (SF-36) scores. In TG at Week 4, the HHS and VAS score were significantly improved compared to PG, and pairwise assessments showed significant improvements in HSS and VAS pain at each time point compared to baseline for TG. No significant changes were observed in MRC and SF-36 over time, though SF-36 showed a positive trend. There were no significant differences from baseline in the PG. No adverse events were detected in either treatment group. AboBoNT-A injections in hip OA improve range of motion and pain without any significant side effects. View Full-Text
Keywords: botulinum toxin; hip; osteoarthritis; rehabilitation; pain botulinum toxin; hip; osteoarthritis; rehabilitation; pain
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Eleopra, R.; Rinaldo, S.; Lettieri, C.; Santamato, A.; Bortolotti, P.; Lentino, C.; Tamborino, C.; Causero, A.; Devigili, G. AbobotulinumtoxinA: A New Therapy for Hip Osteoarthritis. A Prospective Randomized Double-Blind Multicenter Study. Toxins 2018, 10, 448.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top